GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (XSWX:SANN) » Definitions » Return-on-Tangible-Equity

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Return-on-Tangible-Equity : 0.00% (As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Santhera Pharmaceuticals Holding AG's annualized net income for the quarter that ended in Jun. 2023 was CHF-46.67 Mil. Santhera Pharmaceuticals Holding AG's average shareholder tangible equity for the quarter that ended in Jun. 2023 was CHF-98.37 Mil. Therefore, Santhera Pharmaceuticals Holding AG's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 was N/A%.

The historical rank and industry rank for Santhera Pharmaceuticals Holding AG's Return-on-Tangible-Equity or its related term are showing as below:

During the past 13 years, Santhera Pharmaceuticals Holding AG's highest Return-on-Tangible-Equity was 13.26%. The lowest was -182.42%. And the median was -99.89%.

XSWX:SANN's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -46.56
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Santhera Pharmaceuticals Holding AG Return-on-Tangible-Equity Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG Return-on-Tangible-Equity Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Santhera Pharmaceuticals Holding AG's Return-on-Tangible-Equity

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Return-on-Tangible-Equity falls into.



Santhera Pharmaceuticals Holding AG Return-on-Tangible-Equity Calculation

Santhera Pharmaceuticals Holding AG's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-71.076/( (-63.268+-102.892 )/ 2 )
=-71.076/-83.08
=N/A %

Santhera Pharmaceuticals Holding AG's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=-46.672/( (-102.892+-93.85)/ 2 )
=-46.672/-98.371
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Santhera Pharmaceuticals Holding AG  (XSWX:SANN) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Santhera Pharmaceuticals Holding AG Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Santhera Pharmaceuticals Holding AG (XSWX:SANN) Business Description

Traded in Other Exchanges
Address
Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Headlines

No Headlines